Extrait

This is an open-label extension study of another study protocol, MCS-2-TWN-a. Subjects who have completed the 12-week treatment and procedures under the protocol MCS-2-TWN-a will be eligible for this study.

Critère d'inclusion

• Lower urinary tract symptoms ,benign prostatic hyperplasia

Liens

• nct